Stay updated on RT+Nivolumab+Ipilimumab vs RT+Capecitabine Clinical Trial
Sign up to get notified when there's something new on the RT+Nivolumab+Ipilimumab vs RT+Capecitabine Clinical Trial page.

Latest updates to the RT+Nivolumab+Ipilimumab vs RT+Capecitabine Clinical Trial page
- CheckyesterdayChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check8 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check16 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check23 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check45 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check59 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed descriptions of a clinical trial for Triple Negative Breast Cancer and the addition of a new trial identifier, ET17-093 BreastImmune03, along with a revision update to v2.15.0.SummaryDifference38%
Stay in the know with updates to RT+Nivolumab+Ipilimumab vs RT+Capecitabine Clinical Trial
Enter your email address, and we'll notify you when there's something new on the RT+Nivolumab+Ipilimumab vs RT+Capecitabine Clinical Trial page.